Introduction
Renal cell carcinoma (RCC) is estimated to be the sixth and eighth most frequently diagnosed cancer in men and women, respectively, in 2021 in the United States. Globally, RCC poses a significant healthcare burden with >400,000 new cases and >175,000 attributable deaths annually. Over 20% of patients diagnosed with RCC present with synchronous metastases and 30% of patients who are treated with nephrectomy in a curative intent subsequently develop recurrent metastatic disease. RCC comprises a diverse group of malignancies with increasingly defined genomic features and clinical outcomes. Histologically, it is broadly divided into clear cell RCC (ccRCC) which accounts for approximately 75% of cases and non-clear cell RCC (ncRCC) comprising the remaining 25% of cases.

A landmark breakthrough discovery in the biology of ccRCC was achieved when it was recognized that the majority of sporadic ccRCC cases are driven by inactivating mutations or methylation of von Hippel-Lindau (VHL), leading to accumulation of hypoxia-inducible factor (HIF) which in turn leads to activation of pathways that promote angiogenesis such as the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Furthermore, RCC is known to be one of the most immune-responsive solid tumors with a frequent high infiltration of several immune cells. As our understanding of the disease biology and molecular interplay in RCC improved, this led to an expansion of the therapeutic landscape of metastatic RCC over the last two decades, which resulted in a plethora of FDA-approved drugs, including therapies targeting tyrosine kinase inhibitors with activity against the VEGF receptor, antibodies directed against VEGF, small molecule inhibitors of mammalian target of rapamycin (mTOR), and more recently, immune checkpoint inhibitors (ICIs) targeting the PD-1/PDL-1 and CTLA-4 axis. As per contemporary guidelines and based on recent randomized phase III studies, the current standard first-line treatment for patients with metastatic RCC consist of dual immune checkpoint inhibition with anti-PD1 plus anti-CTLA-4 ICIs or the combination of anti-VEGF receptor TKI (VEGF-TKI) plus anti-PD-1 ICI.

Novel emerging biomarkers to immunotherapy in kidney cancer

Yasser Ged and Martin H. Voss

Abstract: The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ultimately require salvage therapies. An ever deeper understanding of the disease biology mediated by the development of multiple high-throughput molecular omics has led to significant progress in biomarkers discovery. But despite growing insights into the molecular underpinnings of the tumor microenvironment, biomarkers have not been integrated successfully into clinical practice. In this review, we discuss some of the novel emerging predictive biomarkers to ICIs in metastatic renal cell carcinoma.

Keywords: biomarkers, immune checkpoint, precision medicine, RCC

Received: 9 July 2021; revised manuscript accepted: 25 October 2021.
Relevantly, despite these advances in immuno-therapy in RCC, hitherto, the role of biomarkers was limited on the pivotal trials for these newly approved standards and few metrics help predict treatment responses, durable benefit or early disease progression.\(^{16,17}\) Currently, survival probability can be best estimated using prognostic risk models, including the Memorial Sloan Kettering Cancer Center (MSKCC) risk score,\(^{18}\) developed during the cytokine era, and the International Metastatic RCC Database Consortium (IMDC) risk score,\(^{19}\) developed in the targeted therapy era (Table 1). Both models are computed based on clinical and laboratory variables; however, their applicability and accuracy in the current immunotherapy era may be compromised as ICI now represent the backbone therapy in metastatic RCC.\(^{20}\)

| Risk model | Variables | Risk groups |
|------------|-----------|-------------|
| MSKCC      | Time to initiation of systemic therapy <1 year from diagnosis | Favorable risk = 0 factors Intermediate risk = 1–2 factors Poor risk = 3 or more factors |
|            | Anemia    |             |
|            | Hypercalcemia |         |
|            | Elevated lactate dehydrogenase |           |
|            | Low KPS <80% |          |
| IMDC       | Time to initiation of systemic therapy <1 year from diagnosis | Favorable risk = 0 factors Intermediate risk = 1–2 factors Poor risk = 3 or more factors |
|            | Anemia    |             |
|            | Hypercalcemia |         |
|            | Elevated neutrophils |          |
|            | Elevated platelets |        |
|            | Low KPS <80% |          |

IMDC, International Metastatic RCC Database Consortium; KPS, Karnofsky performance status; MSKCC, Memorial Sloan Kettering Cancer Center; RCC, renal cell carcinoma.

Table 1. Prognostic models for metastatic RCC.

Biomarkers discovery in RCC has been challenging due to multiple factors, including the diverse molecular and genomic heterogeneity of RCC and the fact that the driving genomic events in RCC are primarily due to loss of function events rather than actionable gain of function mutations.\(^{21–23}\) Herein, we will review some of the emerging data in the context of ICI therapy for metastatic disease, including circulating and tissue-based biomarkers.

Programmed death-ligand 1 expression
Program death ligand-1 (PD-L1) is the ligand for PD-1, a key immune checkpoint receptor expressed by activated T cells that has been successfully targeted by multiple checkpoint inhibitors.\(^{24}\) High PD-L1 expression by immunohistochemistry (IHC) on tumor cells is a well-known adverse prognostic factor in patients with metastatic RCC treated with TKI therapy and is associated with aggressive features of RCC, such as a high nuclear grade, lymph node involvement, and metastatic disease.\(^{25,26}\) In the immunotherapy era, PD-L1 expression by IHC is by far the most widely studied biomarker;\(^{27}\) however, unlike other solid tumors like non-small cell lung cancer where PD-L1 expression is incorporated in treatment decisions,\(^{28}\) the role of PD-L1 expression in directing kidney cancer treatment is still debatable, and currently it is not used in our treatment decision making.\(^{15}\) Widely acknowledged limitations of PD-L1 IHC include the spatial heterogeneity of PD-L1 expression within the biopsied lesion.\(^{29,30}\)
the expression of PD-L1 in a wide range of cells in the tumor microenvironment,\textsuperscript{31} and the lack of standardization with different antibody tests and methods to evaluate PD-L1 expression (tumor cells, immune cells, or both).\textsuperscript{32}

The phase III CheckMate 025 clinical trial compared nivolumab with everolimus in patients with previously treated metastatic ccRCC and demonstrated overall survival (OS) benefit for patients treated with nivolumab compared with patients treated with everolimus [25.0 versus 19.6 months; hazard ratio (HR) = 0.73, 98.5\% confidence interval (CI) = 0.57–0.93] irrespective of PD-L1 expression.\textsuperscript{33} In the subgroup analysis of the study, an inferior OS was observed in patients with PD-L1 expression $\geq 1\%$ compared with those with PD-L1 expression $<1\%$. The phase III Checkmate 214 clinical trial investigated the combination of nivolumab plus ipilimumab with sunitinib in previously untreated metastatic ccRCC, the study led to a significant prolongation of OS and progression free survival (PFS), as well as higher objective response rates (ORR) in patients treated with the combination.\textsuperscript{34} In an exploratory analysis, OS and ORR favored nivolumab plus ipilimumab irrespective of PD-L1 expression; however, the benefit was more pronounced in the PD-L1 positive group. In particular, the ORR to the combination was higher in the PD-L1-positive group (ORR among patients with $<1\%$ PD-L1 37\% versus 58\% among patients with $\geq 1\%$ PD-L1), suggesting that PD-L1 expression on tumor cells is not only prognostic but also predictive for this particular regimen.

With regard to ICI plus VEGF-TKI combinations, several combinations reported significant prolongation of PFS, OS, and likelihood of response irrespective of PD-L1 expression when compared with sunitinib including pembrolizumab plus axitinib in the KEYNOTE-426 phase III clinical trial,\textsuperscript{35} nivolumab plus cabozantinib in the CheckMate 9ER phase III clinical trial,\textsuperscript{36} and pembrolizumab plus lenvatinib in the CLEAR phase III clinical trial.\textsuperscript{37} Given the broad efficacy (and superiority over TKI monotherapy) observed with all approved combinations, regardless of PD-L1 expression levels, it has neither been approved nor embraced as a clinical biomarker in this disease.

**Genomic alterations**

Large-scale sequencing efforts have studied the association between clinical outcomes to ICI and the genomic landscape of clear cell RCC, including genomic and copy number alterations. In several solid tumors such as non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC), it was demonstrated that tumor mutational load is associated with improved clinical outcomes to tumor mutational load.\textsuperscript{38,39} This stems from the hypothesis that in tumors with a high mutational load, there is an increased production of neoantigens, which subsequently stimulates the anti-tumor immune systemic response.\textsuperscript{40,41} In 2020, a tumor-agnostic approval was announced by the FDA for pembrolizumab in patients with tissue tumor mutational burden–high (TMB-H; $\geq 10$ mutations/megabase), who have progressed following prior treatment and have no satisfactory alternative treatment options.\textsuperscript{42}

However, RCC is known to exhibit low tumor mutational load with a median of 1.1 mutations per megabase,\textsuperscript{43,44} and correlation has not been demonstrated with response to ICI based on several retrospective and prospective studies.\textsuperscript{45–48} This lack of association extends to exploratory analyses of frontline combination regimens, in that TMB did not correlate with outcomes on CheckMate 214 (ipilimumab plus nivolumab),\textsuperscript{49} JAVELIN renal 101 study (axitinib plusavelumab),\textsuperscript{50} or KEYNOTE 146 (pembrolizumab plus lenvatinib).\textsuperscript{51}

The mammalian SWItch/Sucrose Non-Fermentable complex (mSWI/SNF) is a chromatin remodeling complex that has recently been implicated as a potential biomarker for immunotherapy, in particular the polybromo and BRG-1 associated factors (PBAF) complex; this includes the genes ARID2, PBRM1, and BRD7.\textsuperscript{52} While early reports suggested that LOF alterations in $PBRM1$ might be predictive of benefit from ICI monotherapy with nivolumab,\textsuperscript{53,54} this could not be confirmed in other retrospective\textsuperscript{55} and prospective datasets.\textsuperscript{48–50} ARID1A is another member of the mSWI/SNF, which has been studied as a biomarker of clinical benefit to ICI.\textsuperscript{56,57} Correlative analyses from the phase III IMmotion 151 study demonstrated that the presence of loss of function mutations in ARID1A conferred significant improved PFS treated with atezolizumab plus bevacizumab versus sunitinib (ARID1A altered versus wild type, $HR=0.50$; 95\% CI: 0.26–0.96; median PFS: 20.7 versus 6.8 months).\textsuperscript{58}
DNA damage and repair (DDR) gene alterations are associated with improved outcomes to ICI such as in other solid tumor malignancies. In RCC, analysis of a select panel of key DDR gene alterations (34 genes) across 229 patients showed that deleterious DDR gene alterations were frequent (19%). The presence of DDR gene alteration was associated with improved OS to IO treatment and not associated with outcome in TKI-treated patients. Another study of patients with metastatic RCC (n=34) treated with ICI showed that patients with disease control displayed enrichment of mutations in DNA repair genes.

The significance of copy number alterations was tested in a pooled analysis from three clinical trials (CheckMate 025, 009, 010). Overall, copy number burden did not affect survival; however, loss of 9p21.3 was associated with worse OS following ICI treatment (p=0.011). Similar associations have been demonstrated in other diseases.

Human endogenous retroviruses (ERVs) are remnants of exogenous retroviruses that have integrated into the human genome throughout evolution. In a case series of patients with metastatic ccRCC who received hematopoietic stem cell transplant, a CD8+ T-cell clone was isolated from a long-term responding patient and was found to have recognized a tumor antigen encoded by human endogenous retrovirus type-E (ERV-E). Several studies since have reported that ERVs are aberrantly expressed in ccRCC. A pan-cancer TCGA analysis identified the prevalence of potentially immunogenic ERVs across solid tumors, notably with highest expression in ccRCC, breast cancer, colon cancer, and head and neck squamous cell cancer. The authors found that expression of ERV 3-2, the most prevalent ERV, was enriched in ICI responders compared with non-responders in 24 patients with metastatic ccRCC. Similar findings have since been reported for two additional ERVs (ERV2282 and EVR3382), which were weakly potentially associated with clinical outcomes in a separate anti-PD-1-treated cohort. However, in a recent biomarker analysis of patients treated with metastatic RCC treated on the phase III CheckMate-025 clinical trial, none of the previously identified ERVs were found to be associated with clinical outcomes in the ICI arm.

**Gene expression signatures**

While tumor genomics has proven to be of limited use in predicting benefit from ICI therapies, expression analyses on the RNA level are increasingly helpful to gain insights into the complexities of the immune microenvironment and hold promise for RCC biomarker development in the context of immunotherapies.

Gene expression profiling (GEP) of bulk RNA has helped delineate different molecular subtypes of conventional RCC which were evaluated in several clinical trials (Table 2). Exploratory analyses from the phase II IMmotion150 study (atezolizumab plus bevacizumab versus sunitinib) identified three unique signatures including angiogenesis, pre-existing T effector immune activation, and myeloid inflammation. Tumors with a high versus low angiogenesis signature were found to derive added benefit from sunitinib monotherapy, while such associations were not seen on the other treatment arms. Similarly, high versus low T-effector signature correlated with improved PFS and ORR for patients receiving atezolizumab plus bevacizumab and a trend for the same with atezolizumab alone, but this was not the case in patients treated on the sunitinib arm. Finally, in patients with T-effector high tumors and with a concurrent increase in myeloid infiltration, clear benefit with the addition of bevacizumab was observed, while the combination did not appear to add much in patients with tumors that were T effector high/myeloid low.

A similar approach was conducted in the phase III clinical trial JAVELIN Renal 101 (avelumab plus axitinib versus sunitinib). In this study, the investigators developed a novel immune GEP signature referred to as ‘JAVELIN Renal 101 Immuno’, which is derived from 26 genes involved in T-cell receptor signaling, proliferation, NK cell mediated cytotoxicity, chemokines, and other immune response genes. In the avelumab plus axitinib arm, patients with high expression of this signature had improved median PFS of 15.2 months versus 9.8 months in those with lower expression (HR = 0.60, 95% CI = 0.44–0.83; p = 0.0019); there was no impact of this signature in the sunitinib arm. The authors also proposed a distinct GEP signature of 26 mostly angiogenic genes that could predict outcomes in the sunitinib arm referred to as ‘JAVELIN Renal 101 Angio’. In this study, Weighted Gene Coexpression Network Analysis was used to identify the Javelin Renal 101 transcriptomic signatures. Different authors subsequently applied GEP signatures from IMmotion 150 and JAVELIN Renal...
101 studies to the biomarker cohort of Checkmate 214 study (nivolumab plus ipilimumab versus atezolizumab versus sunitinib), and no correlation with benefit from nivolumab plus ipilimumab was observed. The investigators also conducted a hallmark gene set enrichment analysis as part of the biomarker analyses in Checkmate 214 and found that tumor necrosis factor alpha (TNF alpha) and epithelial-mesenchymal transition (EMT) gene sets expression was higher among patients with PFS >18 months treated with nivolumab plus ipilimumab. In a separate effort, authors assessed IMmotion 150 and JAVELIN Renal 101 GEP signatures in a pooled analysis from three nivolumab monotherapy trials and could not confirm an association between the signatures and clinical outcomes. Authors on the IMmotion 151 phase III study (atezolizumab plus bevacizumab versus atezolizumab versus sunitinib) (n = 263 included in biomarker analysis), using bulk RNA sequencing and targeted mutation sequencing by utilizing the non-negative matrix factorization method, proposed an integrated molecular classification of metastatic ccRCC with delineation of seven transcriptionally defined and genomically annotated, biologically distinct categories of tumors. Treatment effects on the trial were then put in the context of these multi-omics subgroups. The authors broadly grouped patients into clusters with angiogenic phenotypes (clusters 1 and 2) and proliferative phenotypes (clusters 4–6). Clusters 1 and 2 are highly angiogenic, enriched with PBRM1 and KDM5 C mutation, and they were associated with improved outcomes to sunitinib. Cluster 3 had a high expression of cell cycle and complement cascade genes, as well as genes associated with the cytochrome P450 family, which is involved in omega oxidation. This cluster was also associated with low expression of angiogenesis and immune-related genes with relatively poor clinical outcomes regardless of the type of treatment received. Cluster 4 had a high expression of cell cycle and complement cascade genes, as well as genes associated with PBRM1 and KDM5 C mutation, and they were associated with improved outcomes to sunitinib. Cluster 5 had a high expression of cell cycle and complement cascade genes, as well as genes associated with the cytochrome P450 family, which is involved in omega oxidation. This cluster was also associated with low expression of angiogenesis and immune-related genes with relatively poor clinical outcomes regardless of the type of treatment received. Cluster 4 was enriched with T-effectector gene signatures with improved outcomes to ICI and characterized as highly immunogenic with an expression of immune-related genes, high PD-L1 expression, and immune cell infiltration. Cluster 5 displayed a low rate of VHL.
mutation and included sarcomatoid dedifferentiation as well as 15 patients who were found to be of MiT family translocation RCC (tRCC). Cluster 6 was associated with prominent stroma and myeloid signatures. Overall, Clusters 5 and 6 were associated with improved outcomes to ICI but less pronounced compared with Cluster 4. Cluster 7 was a small cohort representing 3% of all tumors which is characterized by high expression of small nucleolar RNAs (snoRNAs) and low mutation rates.

Investigators with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently reported comprehensive proteogenomic analyses of 103 ccRCC tumors and 83 samples of normal adjacent tissue. Previously described GES were then applied. Based on the combined analyses of RNA, proteome, and phospho-proteome, four immune-based ccRCC were identified, discriminated by relative immune and stromal infiltration including (1)CD8+ inflamed; characterized by high CD8+ T cell infiltration, increased expression of the immune evasion markers PD1/PD-L1/PD-L2/CTLA4, high BAP1 mutations, and interferon-gamma signaling. This cluster was also strongly associated with elevated IMmotion 150 T effector signature; (2) CD8− inflamed; characterized by enriched signatures of platelet degranulation, EMT, complement, and coagulation cascades; (3) VEGF immune desert, characterized by enriched signatures of angiogenesis, notch signaling, and Rap1 signaling. Notably, IMmotion 150 angiogenesis signature was enriched in this cluster. (4) Metabolic immune desert, characterized by enriched signatures of angiogenesis, notch signaling, and Rap1 signaling. Notably, IMmotion 150 angiogenesis signature was enriched in this cluster.

Peripheral blood biomarkers

Investigators have evaluated the impact of readily available, routinely used but also that of novel peripheral blood biomarkers in the context of ICI and metastatic RCC. Several authors have explored complete blood cell counts, particularly the distribution of leukocyte subsets in this regard. In a retrospective cohort of 90 patients receiving nivolumab therapy, the risk of progressive disease was increased with a higher baseline neutrophil-to-lymphocyte ratio (NLR) (HR = 1.86, 95% CI, 1.05–3.29), whereas a higher baseline eosinophil count was associated with a lower risk of progression (HR, 0.54; 95% CI, 0.30–0.98; p = 0.042). In a similar analysis, a retrospective review of 142 patients treated with ICI suggested that early decline of NLR at 6 weeks after the initiation of ICI was associated with significantly improved outcomes. In a cohort of 111 patients with metastatic ccRCC treated with nivolumab plus ipilimumab, low baseline neutrophil-to-eosinophil ratio (NER) was associated with significant improvement in PFS, OS, and ORR. However, low baseline NLR was only associated with significant improvement in OS but not in PFS or ORR. Notable opportunities but also challenges lie in the task of integrating these various RNA-based signatures, making them available to the scientific community at large, and ideally simplifying them to the extent that molecular selection can be prospectively applied and integrated into innovative clinical trial concepts.

C-reactive protein (CRP) is a known peripheral serum biomarker of inflammation, and prior performances in most cases. This highlights the important difference between the associations with better survival outcomes and predictive potential; the latter is an essential requirement for the application of these signatures in clinical practice.
studies showed that high baseline CRP is associated with worse OS in patients treated with systemic therapies, including VEGF-TKI and nivolumab.79,80 A recent retrospective study identified that a significant decline in CRP within 3 months of initiation of ICI is associated with improved ORR and PFS, suggestive that CRP kinetics could help to identify early disease progression.81

Circulating cytokines have been studied in kidney cancer as a potential biomarker of systemic therapy, including with targeted therapies and recently with ICI.82,83 A recent prospective correlative study examined the association between distinct pre and on-treatment circulating cytokines with clinical outcomes in 56 patients with metastatic RCC treated ICI or VEGF-TKI.84 Pretreatment cytokine levels did not have an impact on clinical outcomes from ICI in this cohort, but the investigators found that patients who derived clinical benefit (defined as PR, CR, or SD at 6 months) had higher relative increases in levels of IFN-gamma and IL-12 from baseline to 1 month on treatment.

In a pooled analysis from multiple randomized trials representing 1445 patients with metastatic UC or metastatic RCC treated with atezolizumab,85 high baseline levels of IL-8 in plasma, peripheral blood mononuclear cells, and in tumors were associated with decreased efficacy of atezolizumab in patients with metastatic UC and metastatic RCC. In a phase II study of atezolizumab plus bevacizumab in patients with advanced nccc RCC, circulating cytokines were collected at baseline and on treatment.86 Results showed that high baseline levels of specific immunosuppressive cytokines (IL1α, IL6, CCL4, and IL13) were associated with inferior PFS and OS. A decline in these markers on-therapy was not predictive of outcomes.

Microbiome
In recent years, the microbiome has emerged as a key component of the host immune system and has been increasingly recognized for its role in cancer biology.89 This extends to its interplay with cancer therapies, and several studies have pointed to an association between the gut microbiome and outcomes to ICI therapy in solid tumors, highlighting the significance of microbial diversity but also specific bacterial species in this context.90,91

A previously reported prospective observational study collected stool from 31 patients with metastatic RCC prior to initiating ICI therapy (including nivolumab monotherapy and nivolumab plus ipilimumab combination).92 Gut microbiota composition was assessed using whole-genome shotgun metagenomic sequencing. Clinical benefit [defined as partial response (PR), complete response (CR), or stable disease (SD) > 4 months] was associated with greater alpha diversity and the relative abundance of Akkermansia spp. In a separate study, investigators analyzed the gut microbiome from stool samples obtained from 69 advanced RCC patients who were treated with nivolumab as part of the phase II GETUG-AFU 26 NIVOREN.93 Their work identified that recent antibiotic use reduced the ORR to nivolumab (from 28% to 9%, \( p < 0.03 \)), which the authors speculated may have been related to the effect of antibiotics on modulating the gut microbiome to a less favorable ‘gut immune-environment’.

Building on the knowledge of the gut microbiome’s role in modulating outcomes to ICI, a recent phase II study investigated the use of nivolumab plus ipilimumab with or without the...
addition of CBM-588 in patients with metastatic ccRCC. CBM-588 is a probiotic comprised of Clostridium butyricum, which was shown to augment the activity of ICI in non-small cell lung cancer through the modulation of gut microbiota. In this study, among 29 evaluable patients with metastatic ccRCC, the primary endpoint of detectable change in gut microbiome was not reached, however, the ORR was significantly higher among patients receiving nivolumab plus ipilimumab plus CBM-588 compared with those receiving nivolumab plus ipilimumab (59% versus 11%; \( p = 0.024 \)).

### Biomarker-driven clinical trials

With the considerable progress in molecular diagnostics, biomarkers-driven clinical trials have gained interest in recent years. The BIONIKK trial was a phase II biomarker-driven clinical trial evaluating nivolumab versus nivolumab plus ipilimumab versus VEGF-TKI (sunitinib or pazopanib) with treatment assignment per baseline molecular strata. The design of the study was informed by transcriptomic analysis conducted by Beuselinck et al. based on the tumor micro-environment features of 53 primary ccRCC tumors from patients who were treated with sunitinib in the first-line setting. They identified four distinct ccRCC clusters (ccrc1 to 4); ccrcc1 ‘immune-low’ and ccrcc4 ‘immune-high’ tumors were associated with worse outcomes to sunitinib. In contrast, ccrcc2 ‘angio-high’ and ccrcc3 ‘normal-like’ tumors were associated with improved outcomes to sunitinib. According to ccrcc1-4 clusters, patients were randomized to nivolumab or nivolumab plus ipilimumab or VEGF-TKI (sunitinib or pazopanib) with the primary endpoint of ORR. Patients within ccrcc 2 ‘angio-high’ cluster achieved high responses with VEGF-TKI as expected given the enriched angiogenic signatures in this group. ORR was comparable between nivolumab and nivolumab plus ipilimumab in the ‘immune-high’ ccrcc4 group; however, ORR for nivolumab plus ipilimumab was numerically higher than nivolumab alone in the ccrcc1 group ‘immune-low’. The study highlights the need for adequate sample sizes in multi-arm biomarker directed trials, but <1 month turnaround of RNA-based profiling demonstrates that expression-based treatment assignment can be achieved and hence sets the bar for future investigations. Table 3 summarizes some of the ongoing biomarker-driven clinical trials in clear cell RCC.

### Conclusion

With the tremendous expansion in therapeutic armamentarium of kidney cancer, the fast pace of immunotherapeutic innovation, and rapidly evolving methodology to molecularly annotate patient-derived specimens, there is an unprecedented need to develop clinically applicable biomarkers. Novel biomarker discovery endeavors should focus on incorporating different types of biomarkers (clinical, genomic, transcriptomic, blood-based variables) in an effort to build a composite ‘score’ that would help to assess more comprehensively the molecular characteristics of the tumor and the corresponding response to ICIs. The emphasis of the field must be on delineation...
of rational molecular endpoints which can inform the design of large registries and ultimately that of innovative, biomarker-driven clinical trials. For this bright future in kidney cancer biomarkers discovery to materialize and have the clinical impact we seek, we need to learn from prior failures and change the culture to pursue biomarker discovery early, as an integral part of all prospective efforts of developing novel therapeutic strategies.

**Author contributions**

YG: Concept, manuscript writing and approval
MHV: Concept, manuscript writing and approval

**Conflict of interest statement**
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.H.V. reports receiving commercial research grants from Bristol-Myers Squibb, Pfizer, and Genentech/Roche; honoraria from Novartis, BMS travel/accommodation from Astra Zeneca, Eisai, Novartis, and Takeda; consultant/advisory board member for Alexion Pharmaceuticals, Aveo, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Merck, and Naterra; Onquality Pharmaceuticals; Novartis; and Pfizer. Y.G. is consultant/advisory board member for Exelixis and Aveo.

**Funding**
The authors received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. *CA Cancer J Clin* 2021; 71: 7–33.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; 71: 209–249.
3. Cohen HT and McGovern FJ. Renal-cell carcinoma. *N Engl J Med* 2005; 353: 2477–2490.
4. Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol* 2012; 23: 973–980.
5. Manley BJ and Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. *Curr Opin Urol* 2016; 26: 383–387.
6. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. *Nat Genet* 2014; 46: 225–233.
7. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. *Eur Urol* 2016; 70: 93–105.
8. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 1993; 260: 1317–1320.
9. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nat Rev Cancer* 2008; 8: 865–873.
10. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. *Cancer Res* 2001; 61: 5132–5136.
11. Choueiri TK and Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. *N Engl J Med* 2017; 376: 354–366.
12. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. *Nat Rev Dis Primers* 2017; 3: 17009.
13. Kotecha RR, Motzer RJ and Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. *Nat Rev Clin Oncol* 2019; 16: 621–633.
14. McKay RR, Bosse D and Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. *J Clin Oncol*. Epub ahead of print 29 October 2018. DOI: 10.1200/JCO.2018.79.0253.
15. Motzer RJ, Jonasch E, Boyle S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. *J Natl Compr Canc Neto* 2020; 18: 1160–1170.
16. Schmidt AL, Siefker-Radtke A, McConkey D, et al. Renal cell and urothelial carcinoma: biomarkers for new treatments. *Am Soc Clin Oncol Educ Book* 2020; 40: 1–11.
17. Farber NJ, Kim CJ, Modi PK, et al. Renal cell carcinoma: the search for a reliable biomarker. *Transl Cancer Res* 2017; 6: 620–632.
18. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials
of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002; 20: 289–296.

19. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. *J Clin Oncol* 2009; 27: 5794–5799.

20. Single N. A new therapeutic era for metastatic renal cell carcinoma: call for a new prognostic model. *JAMA Oncol* 2020; 6: 633–634.

21. Casuscelli J, Vano YA, Fridman WH, et al. Molecular classification of renal cell carcinoma and its implication in future clinical practice. *Kidney Cancer* 2017; 1: 3–13.

22. Chen F, Zhang Y, Senbabaoglu Y, et al. Multilevel genomics-based taxonomy of renal cell carcinoma. *Cell Rep* 2016; 14: 2476–2489.

23. Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. *Cell Rep* 2018; 23: 313–326.e5.

24. He X and Xu C. Immune checkpoint signaling and cancer immunotherapy. *Cell Res* 2020; 30: 660–669.

25. Thompson RH, Dong H and Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. *Clin Cancer Res* 2007; 13: 709s–715s.

26. Iacovelli R, Nole F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. *Target Oncol* 2016; 11: 143–148.

27. Patel SP and Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Cancer Ther* 2015; 14: 847–856.

28. Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. *J Natl Compr Canc Netw* 2021; 19: 254–266.

29. Zhou KI, Peterson B, Serritella A, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. *Clin Cancer Res* 2020; 26: 6453–6463.

30. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. *JAMA Oncol* 2016; 2: 46–54.

31. Zou W and Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol* 2008; 8: 467–477.

32. Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. *Diagn Pathol* 2018; 13: 12.

33. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; 373: 1803–1813.

34. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med* 2018; 378: 1277–1290.

35. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019; 380: 1116–1127.

36. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2021; 384: 829–841.

37. Motzer R, Alekseev B, Rha SY, et al. Pembrolizumab plus nivolumab or everolimus for advanced renal cell carcinoma. *N Engl J Med* 2021; 384: 1289–1300.

38. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018; 378: 2093–2104.

39. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019; 51: 202–206.

40. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015; 348: 124–128.

41. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* 2016; 351: 1463–1469.

42. FDA approves pembrolizumab for adults and children with TMB-H solid tumors, 2020, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

43. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 2017; 23: 703–713.

44. Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. *Lancet Oncol* 2017; 18: 1009–1021.
54. Wood MA, Weeder BR, David JK, et al. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. *Genome Med* 2020; 12: 33.

55. Hakimi AA, Atralla K, DiNatale RG, et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. *Nat Commun* 2020; 11: 4168.

56. Wu JN and Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? *Cancer Discov* 2013; 3: 35–43.

57. Okamura R, Kato S, Lee S, et al. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. *J Immunother Cancer* 2020; 8: e000438.

58. Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. *Cancer Cell* 2020; 38: 803–817.e4.

59. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015; 372: 2509–2520.

60. Teo MY, Seier K, Ostrovnyaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/ PD-L1 blockade in advanced urothelial cancers. *J Clin Oncol* 2018; 36: 1685–1694.

61. Ged Y, Chaim JL, DiNatale RG, et al. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. *J Immunother Cancer* 2020; 8: e000230.

62. Adib E, Nassar AH, Akl EW, et al. CDKN2A alterations and response to immunotherapy in solid tumors. *Clin Cancer Res* 2021; 27: 4025–4035.

63. Lower R, Boller K, Hasenmaier B, et al. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. *Proc Natl Acad Sci USA* 1993; 90: 4480–4484.

64. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. *J Clin Invest* 2008; 118: 1099–1109.

65. Panda A, de Cubas AA, Stein M, et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. *JCI Insight* 2018; 3: e121522.

66. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019; 380: 1103–1115.

67. Langfelder P and Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 2008; 9: 559.
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet* 2019; 393: 2404–2415.

69. Brunet JP, Tamayo P, Golub TR, et al. Metagenes and molecular pattern discovery using matrix factorization. *Proc Natl Acad Sci USA* 2004; 101: 4164–4169.

70. Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. *Cell* 2019; 179: 964–983.e31.

71. Banchereau R, Leng N, Zill O, et al. Molecular determinants of response to PD-L1 blockade across tumor types. *Nat Commun* 2021; 12: 3969.

72. Krishna C, DiNatale RG, Kuo F, et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. *Cancer Cell* 2021; 39: 662–677.e6.

73. Braun DA, Street K, Burke KP, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. *Cancer Cell* 2021; 39: 632–648.e8.

74. Bi K, He MX, Bakouny Z, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. *Cancer Cell* 2021; 39: 649–661.e5.

75. Zahoor H, Barata PC, Jia X, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. *J Immunother Cancer* 2018; 6: 107.

76. Lalani AA, Xie W, Martini DJ, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. *J Immunother Cancer* 2018; 6: 5.

77. Tucker MD, Brown LC, Kao C, et al. Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 2021; 39(Suppl. 15): 4563.

78. Bilen MA, Rini BI, Motzer RJ, et al. Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. *J Clin Oncol* 2020; 38(Suppl. 15): 5061.

79. Yasuda Y, Saito K, Yuasa T, et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. *Int J Clin Oncol* 2013; 18: 884–889.

80. Ishihara H, Tachibana H, Takagi T, et al. Predictive impact of peripheral blood markers and C-reactive protein in nivolumab therapy for metastatic renal cell carcinoma. *Target Oncol* 2019; 14: 453–463.

81. Fukuda S, Saito K, Yasuda Y, et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. *J Immunother Cancer* 2021; 9: e001564.

82. Voss MH, Chen D, Marker M, et al. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. *Br J Cancer* 2016; 114: 642–649.

83. Wang R, Zheng J, Shao X, et al. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. *J Immunother Cancer* 2019; 7: 348.

84. Chehrazi-Raffle A, Meza L, Alcantara M, et al. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. *J Immunother Cancer* 2021; 9: e002009.

85. Yuen KC, Liu LF, Gupta V, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. *Nat Med* 2020; 26: 693–698.

86. Flippot R, Bakouny Z, Wei XX, et al. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): dynamic changes on therapy and association with outcomes from a phase II trial. *J Clin Oncol* 2020; 38(Suppl. 6): 740.

87. Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. *Science* 2018; 359: 582–587.

88. Lee CH, DiNatale RG, Chowell D, et al. High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab. *Mol Cancer Res* 2021; 19: 1510–1521.

89. Zitzovágl L, Ayyoub M, Routy B, et al. Microbiome and anticancer immunosurveillance. *Cell* 2016; 165: 276–287.

90. Daly LE, Power DG, O’Reilly A, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. *Br J Cancer* 2017; 116: 310–317.
91. Shaikh FY, White JR, Gills JJ, et al. A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors. *Clin Cancer Res* 2021; 27: 2571–2583.

92. Salgia NJ, Bergerot PG, Maia MC, et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. *Eur Urol* 2020; 78: 498–502.

93. Derosa L, Routy B, Fidelle M, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. *Eur Urol* 2020; 78: 195–206.

94. Meza LA, Dizman N, Bergerot PG, et al. First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2021; 39(Suppl. 15): 4513.

95. Tomita Y, Ikeda T, Sakata S, et al. Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. *Cancer Immunol Res* 2020; 8: 1236–1242.

96. Vano Y, Elaidi RT, Bennamoun M, et al. LBA25 results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial. *Ann Oncol* 2020; 31: S1157.

97. Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. *Clin Cancer Res* 2015; 21: 1329–1339.